Trials / Completed
CompletedNCT00551135
Surgical Pain After Inguinal Hernia Repair (SPAIHR)
A Randomized, Double Blind Multi Center Dose Ranging Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo In The Adjunctive Treatment Of Post Surgical Pain After Primary Inguinal Hernia Repair
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 425 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- Male
- Age
- 17 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test whether pregabalin added to the standard of care with dosing starting preoperatively and continuing for 1 week post surgery will decrease the intensity of acute post-operative pain following inguinal hernia repair.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pregabalin | 150 mg BID |
| DRUG | placebo | Placebo |
| DRUG | Pregabalin | 75 mg BID |
| DRUG | Pregabalin | 25 mg BID |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2009-06-01
- Completion
- 2009-09-01
- First posted
- 2007-10-30
- Last updated
- 2021-01-25
- Results posted
- 2010-07-15
Locations
42 sites across 6 countries: United States, Australia, Canada, India, Spain, Sweden
Source: ClinicalTrials.gov record NCT00551135. Inclusion in this directory is not an endorsement.